Surgery Partners, Inc.

NasdaqGS:SGRY Stock Report

Market Cap: US$2.7b

Surgery Partners Valuation

Is SGRY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SGRY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SGRY ($21.22) is trading below our estimate of fair value ($62.19)

Significantly Below Fair Value: SGRY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SGRY?

Key metric: As SGRY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SGRY. This is calculated by dividing SGRY's market cap by their current revenue.
What is SGRY's PS Ratio?
PS Ratio0.9x
SalesUS$2.99b
Market CapUS$2.68b

Price to Sales Ratio vs Peers

How does SGRY's PS Ratio compare to its peers?

The above table shows the PS ratio for SGRY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.8x
CON Concentra Group Holdings Parent
1.4x5.7%US$2.6b
ARDT Ardent Health Partners
0.4x6.8%US$2.3b
SEM Select Medical Holdings
0.4x3.8%US$2.5b
ACHC Acadia Healthcare Company
1.1x8.4%US$3.5b
SGRY Surgery Partners
0.9x9.3%US$2.7b

Price-To-Sales vs Peers: SGRY is expensive based on its Price-To-Sales Ratio (0.9x) compared to the peer average (0.8x).

Price to Sales Ratio vs Industry

How does SGRY's PS Ratio compare vs other companies in the US Healthcare Industry?

29 CompaniesPrice / SalesEstimated GrowthMarket Cap
MCK McKesson
0.2x8.1%US$73.59b
CVS CVS Health
0.2x4.5%US$55.82b
COR Cencora
0.1x6.4%US$44.01b
CNC Centene
0.2x5.5%US$30.08b
SGRY 0.9xIndustry Avg. 1.0xNo. of Companies29PS012345+
29 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SGRY is good value based on its Price-To-Sales Ratio (0.9x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is SGRY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SGRY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.9x
Fair PS Ratio1x

Price-To-Sales vs Fair Ratio: SGRY is good value based on its Price-To-Sales Ratio (0.9x) compared to the estimated Fair Price-To-Sales Ratio (1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SGRY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$21.22
US$34.94
+64.6%
15.2%US$50.00US$28.00n/a12
Dec ’25US$23.84
US$36.29
+52.2%
13.2%US$50.00US$31.00n/a11
Nov ’25US$28.75
US$39.44
+37.2%
15.0%US$50.00US$32.00n/a12
Oct ’25US$32.49
US$39.27
+20.9%
15.3%US$50.00US$32.00n/a12
Sep ’25US$31.95
US$39.27
+22.9%
15.3%US$50.00US$32.00n/a12
Aug ’25US$30.22
US$39.77
+31.6%
15.0%US$50.00US$31.00n/a12
Jul ’25US$23.41
US$40.25
+71.9%
14.2%US$50.00US$31.00n/a12
Jun ’25US$27.60
US$41.09
+48.9%
12.7%US$50.00US$35.00n/a11
May ’25US$24.63
US$42.36
+72.0%
12.7%US$50.00US$35.00n/a11
Apr ’25US$28.88
US$43.00
+48.9%
11.3%US$50.00US$35.00n/a11
Mar ’25US$31.19
US$43.80
+40.4%
9.9%US$50.00US$36.00n/a10
Feb ’25US$32.53
US$43.80
+34.6%
10.3%US$50.00US$35.00n/a10
Jan ’25US$31.99
US$43.50
+36.0%
9.7%US$50.00US$35.00n/a10
Dec ’24US$34.05
US$43.20
+26.9%
9.4%US$50.00US$35.00US$23.8410
Nov ’24US$22.65
US$46.30
+104.4%
7.7%US$50.00US$39.00US$28.7510
Oct ’24US$29.25
US$48.36
+65.3%
13.3%US$65.00US$39.00US$32.4911
Sep ’24US$37.37
US$48.36
+29.4%
13.3%US$65.00US$39.00US$31.9511
Aug ’24US$36.94
US$48.73
+31.9%
13.9%US$65.00US$39.00US$30.2211
Jul ’24US$44.99
US$48.55
+7.9%
13.9%US$65.00US$39.00US$23.4111
Jun ’24US$38.16
US$47.82
+25.3%
14.6%US$65.00US$39.00US$27.6011
May ’24US$39.37
US$46.10
+17.1%
17.1%US$65.00US$39.00US$24.6310
Apr ’24US$34.47
US$45.40
+31.7%
18.4%US$65.00US$38.00US$28.8810
Mar ’24US$33.99
US$45.20
+33.0%
19.5%US$65.00US$36.00US$31.1910
Feb ’24US$34.66
US$44.40
+28.1%
21.4%US$65.00US$34.00US$32.5310
Jan ’24US$27.86
US$45.30
+62.6%
26.7%US$69.00US$30.00US$31.9910
Dec ’23US$28.56
US$46.60
+63.2%
27.7%US$69.00US$30.00US$34.0510

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:24
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Surgery Partners, Inc. is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Steven ValiquetteBarclays
Sarah JamesBarclays
Andrew MokBarclays